Multivariate biomarker study for sarcopenia in heart failure
Research type
Research Study
Full title
Towards diagnosis of secondary sarcopenia as comorbidity in heart failure: a multivariate biomarker approach
IRAS ID
324573
Contact name
Masoud Isanejad
Contact email
Sponsor organisation
University of Liverpool
Clinicaltrials.gov Identifier
UoL001725, University of Liverpool Sponsor Refrence
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
BACKGROUND
Sarcopenia is the loss of muscle mass and strength. In comparison to primary sarcopenia (age-related sarcopenia), secondary sarcopenia occurs if other factors, including malignancy or organ failure, are evident in addition to aging. Secondary sarcopenia is highly common in patients with heart failure (Sarc-HF) (prevalence is 35%-69%), and has a significant negative impact on exercise capacity, weight-adjusted peak maximal oxygen consumption, left ventricular function and re-hospitalization rates and mortality. Altered appetite leading to reduced food intake, especially via mediators such as ghrelin, adiponectin and leptin that are involved in lipid and glucose metabolism, alongside the reduced capacity of exercise due to cardiac cachexia and changes in cardiac energy metabolism, lead to weight loss and an incremental rate of muscle tissue losses.
AIM
In this integrated study of NHS patients with heart failure (HF), our aim is to identify and test by a multivariate/multidimensional modelling of a panel of complementary biomarkers including body composition, circulating metabolites (metabolic profile), and functional tests for
(1) early detection of otherwise subclinical HF
(2) diagnostic assessment of clinically manifest HF-sarcopenia
(3) the risk stratification of subjects with suspected or confirmed diagnosis
(4) selection of an appropriate therapeutic intervention.
CLINICAL PERSPECTIVE
To investigate the hypothesis that muscle strength loss (sarcopenia) is the result of impaired energy metabolism and comorbidity-induced systemic inflammation, we developed a comprehensive analysis on circulating metabolites (metabolic profile) and circulating proteins via proteomics in the current study and to validate our results externally. Previous studies on HF comorbidities a) did not account for body composition and sarcopenia as a burden, b) they focused on single HF population mainly with not control group.REC name
London - Queen Square Research Ethics Committee
REC reference
23/PR/0050
Date of REC Opinion
3 Apr 2023
REC opinion
Further Information Favourable Opinion